KR20200003859A - 항-혈관신생 펩티드의 지속적인 운반을 위한 생물분해가능한 미립자 - Google Patents

항-혈관신생 펩티드의 지속적인 운반을 위한 생물분해가능한 미립자 Download PDF

Info

Publication number
KR20200003859A
KR20200003859A KR1020197035367A KR20197035367A KR20200003859A KR 20200003859 A KR20200003859 A KR 20200003859A KR 1020197035367 A KR1020197035367 A KR 1020197035367A KR 20197035367 A KR20197035367 A KR 20197035367A KR 20200003859 A KR20200003859 A KR 20200003859A
Authority
KR
South Korea
Prior art keywords
seq
abu
peptide
pharmaceutical composition
particulate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197035367A
Other languages
English (en)
Korean (ko)
Inventor
조던 제이. 그린
니란잔 팬디
알렉산더 에스. 포펠
피터 에이. 캄포치아로
자영 김
라켈 리마 이. 실바
론 쉬뮤엘리
아담 미란도
Original Assignee
아스클리픽스 테라퓨틱스, 인크.
더 존스 홉킨스 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스클리픽스 테라퓨틱스, 인크., 더 존스 홉킨스 유니버시티 filed Critical 아스클리픽스 테라퓨틱스, 인크.
Publication of KR20200003859A publication Critical patent/KR20200003859A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020197035367A 2017-05-08 2018-05-08 항-혈관신생 펩티드의 지속적인 운반을 위한 생물분해가능한 미립자 Ceased KR20200003859A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762502913P 2017-05-08 2017-05-08
US62/502,913 2017-05-08
PCT/US2018/031663 WO2018208829A1 (en) 2017-05-08 2018-05-08 Biodegradable microparticles for sustained delivery of anti-angiogenic peptide

Publications (1)

Publication Number Publication Date
KR20200003859A true KR20200003859A (ko) 2020-01-10

Family

ID=64104968

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197035367A Ceased KR20200003859A (ko) 2017-05-08 2018-05-08 항-혈관신생 펩티드의 지속적인 운반을 위한 생물분해가능한 미립자

Country Status (8)

Country Link
US (1) US20200179285A1 (https=)
EP (1) EP3621597A4 (https=)
JP (1) JP2020518651A (https=)
KR (1) KR20200003859A (https=)
CN (1) CN111315364A (https=)
AU (1) AU2018266690A1 (https=)
CA (1) CA3063140A1 (https=)
WO (1) WO2018208829A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019021056B1 (pt) 2017-04-06 2022-11-22 Sustain Holdings, Llc Usos de uma composição que compreende um peptídeo mimético de colágeno para o tratamento ou a prevenção de uma doença, distúrbio ou ferida ocular
US11674959B2 (en) 2017-08-03 2023-06-13 The Johns Hopkins University Methods for identifying and preparing pharmaceutical agents for activating Tie1 and/or Tie2 receptors
AU2020248438A1 (en) 2019-03-26 2021-10-28 Asclepix Therapeutics, Inc. Compositions and methods for treating ocular disease
EP3958889B1 (en) 2019-04-22 2025-01-08 Sustain Holdings, LLC Collagen mimetic peptide compositions for treating a posterior segment ocular disease or disorder involving the retina, retinal blood vessels, retinal nerves or optic nerve
IT202100023357A1 (it) 2021-09-09 2023-03-09 Cheirontech S R L Peptidi con attività anti-angiogenica
CN117126233A (zh) * 2022-05-20 2023-11-28 杭州禾泰健宇生物科技有限公司 一种类肽化合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717694B2 (en) * 2009-05-15 2017-08-01 The Johns Hopkins University Peptide/particle delivery systems
US10314917B2 (en) * 2013-03-15 2019-06-11 The Brigham And Women's Hospital, Inc. Targeted polymeric inflammation-resolving nanoparticles
US9802984B2 (en) * 2013-06-07 2017-10-31 The Johns Hopkins University Biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases
MX2019003895A (es) * 2016-10-04 2019-10-07 Asclepix Therapeutics Inc Compuestos y metodos para activar la señalizacion tie2.

Also Published As

Publication number Publication date
US20200179285A1 (en) 2020-06-11
WO2018208829A1 (en) 2018-11-15
CA3063140A1 (en) 2018-11-15
WO2018208829A8 (en) 2019-07-04
JP2020518651A (ja) 2020-06-25
EP3621597A4 (en) 2021-06-02
EP3621597A1 (en) 2020-03-18
AU2018266690A1 (en) 2019-12-12
CN111315364A (zh) 2020-06-19

Similar Documents

Publication Publication Date Title
KR20200003859A (ko) 항-혈관신생 펩티드의 지속적인 운반을 위한 생물분해가능한 미립자
Yu et al. Self-assembling peptide nanofibrous hydrogel as a versatile drug delivery platform
EP3424948B1 (en) Vascular endothelial growth factor targeting peptide-elastin fusion polypeptide and self-assembling nanostructure, which are for inhibiting angiogenesis
JP6282231B2 (ja) 固化するデポー形成の注入可能な薬物製剤に懸濁される持続放出された生分解性または生体侵食性微小球または微小粒子
CA2846209C (en) Systemic sustained release formulation comprising elastin­like peptide repeating sequence and protein active agent
Santos et al. Genetically engineered elastin-based biomaterials for biomedical applications
JP2020506232A (ja) ゴナドトロピン放出ホルモン（ＧｎＲＨ）拮抗薬の長期放出のための組成物および方法
ES2699459T3 (es) Nanomatriz que imita endotelio
CN109072241A (zh) 具有改善的玻璃体内半衰期的组合物及其用途
WO1994027630A1 (en) Cross-linked gelatin gel preparation containing basic fibroblast growth factor
JP2000507912A (ja) 作用剤の徐放性組成物
KR20120130752A (ko) 혈관신생-관련된 안질환의 치료를 위한 조성물 및 방법
Rana et al. Recent trends in drug delivery and emerging biomedical applications of gelatin for ophthalmic indications
CA2675953C (en) Therapeutic agent for spinal cord injuries
JP2018515582A (ja) 眼の障害の処置のためのカプセル化細胞療法の使用
JP2020518651A5 (https=)
CN112969451A (zh) 使用α连接蛋白C端肽的纳米粒子制剂和方法
JP7650074B2 (ja) 眼疾患を治療するための組成物及び方法
JP2018526434A (ja) 緑内障用の徐放性薬物配合物
US20150148295A1 (en) Controlled-Released Peptide Formulations
AU2012270024A1 (en) A sustained -release composition containing a melanocortin receptor ligand as the active ingredient
Hameed et al. Controlled Release of Therapeutic Proteins
WO2025259913A2 (en) Peptide-modified ppcn and methods of ocular delivery and treatment of disease therewith
Ruso et al. Biomedical Applications of Recombinant Proteins and Derived Polypeptides
Eskandari et al. ÔØ Å ÒÙ× Ö ÔØ

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191129

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210506

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230718

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230921

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230718

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I